Shopping Cart 0
Cart Subtotal
USD 0

Pharmaceuticals in Scandinavia

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Pharmaceuticals in Scandinavia

Summary

Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Scandinavia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Scandinavian pharmaceuticals market had total revenues of USD 12.8bn in 2017, representing a compound annual rate of change (CARC) of -0.7% between 2013 and 2017.

- Although there is an ageing population which has driven the demand for drugs in Scandinavia, the market has declined due to the prevalence of generics.

- The four Scandinavian component countries are heavily driven by a large government public health market and they have been affected by the trend of western governments to cutting down on pharmaceutical spending, instead trying to encourage greater adoption of generics and cheaper alternatives

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Scandinavia pharmaceuticals market by value in 2017?

- What will be the size of the Scandinavia pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in Scandinavia's pharmaceuticals market?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market Segmentation 10

Geography segmentation 10

Market share 11

Market Outlook 12

Market value forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 16

New entrants 17

Threat of substitutes 19

Degree of rivalry 20

Leading Companies 22

Novartis AG 22

Pfizer Inc. 25

F. Hoffmann-La Roche Ltd 29

Sanofi SA 32

Methodology 35

Industry associations 36

Related MarketLine research 36

Appendix 37

About MarketLine 37


List Of Figure

List of Figures

Figure 1: Scandinavia pharmaceuticals market value: USD billion, 2013-17

Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2017

Figure 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2017

Figure 11: Novartis AG: revenues & profitability

Figure 12: Novartis AG: assets & liabilities

Figure 13: Pfizer Inc.: revenues & profitability

Figure 14: Pfizer Inc.: assets & liabilities

Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability

Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities

Figure 17: Sanofi SA: revenues & profitability

Figure 18: Sanofi SA: assets & liabilities


List Of Table

List of Tables

Table 1: Scandinavia pharmaceuticals market value: USD billion, 2013-17

Table 2: Scandinavia pharmaceuticals market geography segmentation: USD billion, 2017

Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2017

Table 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2017-22

Table 5: Novartis AG: key facts

Table 6: Novartis AG: key financials (USD )

Table 7: Novartis AG: key financial ratios

Table 8: Pfizer Inc.: key facts

Table 9: Pfizer Inc.: key financials (USD )

Table 10: Pfizer Inc.: key financial ratios

Table 11: F. Hoffmann-La Roche Ltd: key facts

Table 12: F. Hoffmann-La Roche Ltd: key financials (USD )

Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)

Table 14: F. Hoffmann-La Roche Ltd: key financial ratios

Table 15: Sanofi SA: key facts

Table 16: Sanofi SA: key financials (USD )

Table 17: Sanofi SA: key financials (EUR)

Table 18: Sanofi SA: key financial ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Pharmaceuticals in Scandinavia

Summary

Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Scandinavia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

- The Scandinavian pharmaceuticals market had total revenues of USD 12.8bn in 2017, representing a compound annual rate of change (CARC) of -0.7% between 2013 and 2017.

- Although there is an ageing population which has driven the demand for drugs in Scandinavia, the market has declined due to the prevalence of generics.

- The four Scandinavian component countries are heavily driven by a large government public health market and they have been affected by the trend of western governments to cutting down on pharmaceutical spending, instead trying to encourage greater adoption of generics and cheaper alternatives

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia

- Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Scandinavia pharmaceuticals market by value in 2017?

- What will be the size of the Scandinavia pharmaceuticals market in 2022?

- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in Scandinavia's pharmaceuticals market?

READ MORE

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 9

Market value 9

Market Segmentation 10

Geography segmentation 10

Market share 11

Market Outlook 12

Market value forecast 12

Five Forces Analysis 13

Summary 13

Buyer power 14

Supplier power 16

New entrants 17

Threat of substitutes 19

Degree of rivalry 20

Leading Companies 22

Novartis AG 22

Pfizer Inc. 25

F. Hoffmann-La Roche Ltd 29

Sanofi SA 32

Methodology 35

Industry associations 36

Related MarketLine research 36

Appendix 37

About MarketLine 37


List Of Figure

List of Figures

Figure 1: Scandinavia pharmaceuticals market value: USD billion, 2013-17

Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2017

Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2017

Figure 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2017

Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2017

Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2017

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2017

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2017

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2017

Figure 11: Novartis AG: revenues & profitability

Figure 12: Novartis AG: assets & liabilities

Figure 13: Pfizer Inc.: revenues & profitability

Figure 14: Pfizer Inc.: assets & liabilities

Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability

Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities

Figure 17: Sanofi SA: revenues & profitability

Figure 18: Sanofi SA: assets & liabilities


List Of Table

List of Tables

Table 1: Scandinavia pharmaceuticals market value: USD billion, 2013-17

Table 2: Scandinavia pharmaceuticals market geography segmentation: USD billion, 2017

Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2017

Table 4: Scandinavia pharmaceuticals market value forecast: USD billion, 2017-22

Table 5: Novartis AG: key facts

Table 6: Novartis AG: key financials (USD )

Table 7: Novartis AG: key financial ratios

Table 8: Pfizer Inc.: key facts

Table 9: Pfizer Inc.: key financials (USD )

Table 10: Pfizer Inc.: key financial ratios

Table 11: F. Hoffmann-La Roche Ltd: key facts

Table 12: F. Hoffmann-La Roche Ltd: key financials (USD )

Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)

Table 14: F. Hoffmann-La Roche Ltd: key financial ratios

Table 15: Sanofi SA: key facts

Table 16: Sanofi SA: key financials (USD )

Table 17: Sanofi SA: key financials (EUR)

Table 18: Sanofi SA: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com